乌司奴单抗诱导克罗恩病患者内镜下愈合的疗效
该研究为3项随机对照3期试验的内镜亚组分析,纳入334例中重度克罗恩病患者,评估乌司奴单抗诱导和维持治疗对内镜下愈合的作用。诱导治疗第8周,乌司奴单抗组SES-CD较基线降低2.8分,安慰剂组降低0.7分(P=0.012)。维持治疗第44周,乌司奴单抗每8周组SES-CD降低3.1分,安慰剂组降低1.9分,但差异未达统计学显著(P=0.107)。
要点
- 乌司奴单抗诱导治疗第8周SES-CD降低2.8分,安慰剂组降低0.7分,差异有统计学意义(P=0.012)。
- 维持治疗第44周,乌司奴单抗每8周组SES-CD降低3.1分,安慰剂组降低1.9分,差异未达统计学显著(P=0.107)。
- 乌司奴单抗静脉诱导和皮下维持治疗可降低中重度克罗恩病患者SES-CD。
核心结论
- 在中重度克罗恩病患者中,乌司奴单抗静脉诱导和皮下维持治疗较安慰剂降低SES-CD。
- 乌司奴单抗诱导治疗第8周观察到内镜下疾病活动度显著降低。
研究设计与样本
- 研究为3项随机对照3期试验的内镜亚组分析,共纳入334例中重度克罗恩病患者。
- 所有患者在诱导研究基线和第8周、维持研究第44周接受结肠镜检查,均由盲法中心阅片者评估。
- 诱导研究期间患者随机接受静脉乌司奴单抗(130 mg或6 mg/kg)或安慰剂。
- 维持研究基线(诱导研究第8周)时,对乌司奴单抗临床应答者随机给予皮下乌司奴单抗(90 mg每12周或每8周)或安慰剂。
- 维持分析人群还包括诱导期间对乌司奴单抗或安慰剂无应答者及对安慰剂应答者,并对随机和非随机患者进行事后汇总分析。
主要发现
- 诱导治疗第8周,乌司奴单抗组SES-CD较诱导基线降低2.8分,安慰剂组降低0.7分(P=0.012)。
- 不同诱导研究和不同乌司奴单抗剂量的患者结果相似。
- 维持治疗第44周,乌司奴单抗合并组SES-CD较诱导基线降低2.5分(P=0.176),每8周组降低3.1分(P=0.107),安慰剂组降低1.9分。
- 较大规模的事后汇总分析中维持治疗结果相似。
关键数值与推荐
- 主要终点为诱导治疗第8周SES-CD较基线的变化。
- 诱导治疗第8周,乌司奴单抗组SES-CD降低2.8分 vs 安慰剂组降低0.7分(P=0.012)。
- 维持治疗第44周,乌司奴单抗合并组SES-CD降低2.5分(P=0.176)vs 安慰剂组降低1.9分;每8周组降低3.1分(P=0.107)vs 安慰剂组降低1.9分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We evaluated the ability of ustekinumab, a monoclonal antibody against the p40 subunit of interleukins 12 and 23, to induce endoscopic healing in patients with moderate to severe Crohn's disease (CD). METHODS: We performed an endoscopy substudy of 334 patients with moderate to severe CD participating in 3 randomized controlled phase 3 studies to determine the safety and efficacy of ustekinumab induction and maintenance therapy. All patients underwent colonoscopy at baseline and week 8 of the induction studies and at week 44 of the maintenance study; all colonoscopies were assessed by a blinded central reader. During the induction studies, patients were randomly assigned to groups given intravenous ustekinumab (130 mg or 6 mg/kg) or placebo. At the baseline time point of the maintenance study (week 8 of the induction studies), patients with a clinical response to ustekinumab were randomly assigned to groups given subcutaneous ustekinumab (90 mg every 12 weeks or 8 weeks) or placebo. Additional maintenance analysis populations were patients who did not respond to ustekinumab or placebo during the induction studies, and patients who responded to placebo during the induction studies; we performed a post-hoc pooled analysis of randomly assigned and non-randomly assigned patients of the maintenance study. We analyzed data from patients with an ulcer in at least 1 segment at baseline of the induction studies. The primary end point was change in the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), from baseline, at week 8. We also assessed the efficacy of maintenance therapy. RESULTS: Patients given ustekinumab had a greater reduction in SES-CD from the induction baseline time point until week 8 than placebo (reduction of 2.8 in patients given ustekinumab vs a reduction of 0.7 points in patients given placebo; P = .012). Results were similar among patients in different induction studies and patients given different doses of ustekinumab. At week 44, reductions in the SES-CD from the induction baseline were greater in patients given ustekinumab (for combined groups, a reduction of 2.5; P = .176 and for every 8 weeks, a reduction of 3.1; P = .107) than patients given placebo (reduction of 1.9 points). Maintenance results were similar for the larger pooled post-hoc analysis. CONCLUSIONS: In an analysis of data from 3 trials of patients with moderate to severe CD, ustekinumab (intravenous induction and subcutaneous maintenance) reduces SES-CD compared with placebo. We observed significant reductions in endoscopic disease activity at week 8 of induction therapy with ustekinumab. (ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355).
引用
- Rutgeerts P, Gasink C, Chan D, et al. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018. PMID: 29909019. doi:10.1053/j.gastro.2018.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。